Pegylated interferon and ribavirin in real life: Efficacy versus effectiveness

Hepatology

Volumn 52, Issue 5, 2010, Pages 1867-

  De Mattos, Ângelo Zambam ^a   De Almeida, Paulo Roberto Lerias ^a,b   Tovo, Cristiane Valle ^a,b   De Mattos, Angelo Alves ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 78049504926     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23824     Document Type: Letter

References (7)

1. Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. HEPATOLOGY 2010; 51: 1137-1143.
2. Almeida PRL, Mattos AA, Amaral KM, Feltrin AA, Zamin P, Tovo CV, et al. Treatment of hepatitis C with peginterferon and ribavirin in a public health program. Hepatogastroenterology 2009; 56: 223-226.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FLJr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 247: 975-982.
6. Marotta P, Hueppe D, Zehnter E, Kwo P, Jacobson I. Efficacy of chronic hepatitis C therapy in community-based trials. Clin Gastroenterol Hepatol 2009; 7: 1028-1035.
7. Pariente A, Djilloul A, Cadranel JF. Treatment of chronic hepatitis C with interferon alpha and ribavirin: results in "real life". Gastroenterol Clin Biol 2003; 27: 590-595.